Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioHarvest Sciences Inc.

Market Cap 7.39Cr 6.45Cr 5.94Cr 5.6Cr 10Cr 697.02Cr 11Cr 71Cr 27Cr 342.97Cr 28Cr 27Cr 1.19TCr P/E 2026 *
-8x
P/E 2027 * -19.8x
Enterprise Value 7.39Cr 6.45Cr 5.94Cr 5.6Cr 10Cr 697.02Cr 11Cr 71Cr 27Cr 342.97Cr 28Cr 27Cr 1.19TCr EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.25x
Free-Float
85.23%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 68 29/04/2026
Director of Finance/CFO - 28/10/2024
Chief Operating Officer 65 19/04/2023
Director TitleAgeSince
Chairman 68 27/09/2018
Director/Board Member 67 27/09/2018
Director/Board Member 84 07/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.06%-2.94% - - 7.44Cr
-0.98%-3.41%-12.82%-9.24% 1.29TCr
-1.84%-4.35%-35.06%-57.81% 485.84Cr
-3.47%-8.90%-12.91%-6.91% 449.78Cr
+0.29%-0.99%+14.53%-16.19% 379.88Cr
+0.47%-2.97%+4.82%-43.79% 369.59Cr
-1.30%-4.39%-6.53%-11.27% 358Cr
-0.07%-1.67%-10.08%-3.49% 311.7Cr
-0.71%+3.95%-6.26%-26.47% 240.16Cr
-1.61%-8.55%-14.35%+29.97% 170.42Cr
Average -0.32%-3.87%-8.74%-16.13% 450.74Cr
Weighted average by Cap. -1.06%-4.31%-10.24%-17.71%

Financials

2026 *2027 *
Net sales 4.29Cr 3.74Cr 3.45Cr 3.25Cr 6.06Cr 404.56Cr 6.11Cr 41Cr 16Cr 199.06Cr 16Cr 16Cr 691.76Cr 5.9Cr 5.14Cr 4.74Cr 4.46Cr 8.33Cr 556.09Cr 8.4Cr 56Cr 22Cr 273.63Cr 22Cr 22Cr 950.88Cr
Net income -92.66L -80.84L -74.52L -70.16L -1.31Cr -87Cr -1.32Cr -8.87Cr -3.44Cr -43Cr -3.48Cr -3.4Cr -149.44Cr -37.73L -32.92L -30.35L -28.57L -53.32L -36Cr -53.77L -3.61Cr -1.4Cr -18Cr -1.42Cr -1.39Cr -61Cr
Net Debt - -
Logo BioHarvest Sciences Inc.
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.260USD
Average target price
12.75USD
Spread / Average Target
+291.10%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!